CTRI/2022/10/046634尚未招募3 期
A Phase III, Prospective, Multi-Center, Double Blind, Comparative, Active Controlled, Parallel Group, Randomized Study to Evaluate the Efficacy and Safety of Trelagliptin in Indian Adult Patients with Type 2 Diabetes Mellitus.
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •1. Adult male or female patients aged of 18-65 years.
- •2. Patients willing to give written, signed, and dated informed consent to participate in the study.
- •3. Newly diagnosed patients with fasting plasma glucose >=126 mg/dL (7.0 mmol/L) and 2-h post prandial plasma glucose >=200 mg/dL (11.1 mmol/L) during oral glucose tolerance test (OGTT) at screening and end of run-in period.
- •4. Patients with Type 2 Diabetes Mellitus and having HbA1C of >=7% at screening and end of run-in period.
- •5. Females of childbearing potential who are sexually active must agree to use barrier contraception and can neither be pregnant nor lactating from screening throughout the duration of the study.
- •6. Clinical laboratory evaluations (including clinical chemistry, hematology, and complete urinalysis) within the reference range for the testing laboratory or the results are deemed not clinically significant for inclusion into this study by the investigator.
排除标准
- •1. Patient with Type 1 diabetes mellitus or secondary diabetes.
- •2. Patients with fasting plasma glucose >=250 mg/dL or >=13.9mmol/L or a history of severe hypoglycemia (blood sugar <=50 mg/dL or <=2.8mmol/L).
- •3. Patients with history of hypersensitivity reactions with DPP-4 inhibitors.
- •4. Patients received insulin within 8 weeks prior to screening.
- •5. Patients received treatment with a PPARγ agent (e.g., pioglitazone or rosiglitazone) or incretin mimetics (e.g., exenatide) within 12 weeks.
- •6. Patients with a body mass index (BMI) < 20 kg/m2 or > 43 kg/m2.
- •7. Patients with history of diabetic nephropathy, diabetic ketoacidosis, diabetic coma, hyperglycemia hyperosmolar state, retinopathy, neuropathy or other diabetic complications requiring treatment like severe symptomatic orthostatic hypotension, urinary retention, foot
- •ulcers, or gastric stasis.
- •8. Patients with clinically significant renal, hepatic, cerebrovascular, gastrointestinal, cardiovascular, nervous, malignancy, thyroid dysfunction, chronic uncontrolled systemic diseases like asthma, hypertension, collagen disorders and severe infection.
- •9. Patients with moderate (30 to < 60 ml/min/1.73 m2) to severe (15 to < 30 ml/min/1.73 m2) renal impairment, as determined at Screening, with GFR as calculated by the Cockcroft-Gault formula.
- •10. Patients with history of acute or chronic liver disease, and Aspartate aminotransferase (AST) or Alanine aminotransferase (ALT) >2.5 X ULN or total bilirubin >1.5 X ULN at the screening period.
- •11. Patients with active heart disease (including acute myocardial infarction, unstable angina within 6 months), congestive heart failure (NYHA class III or IV), percutaneous transluminal coronary angioplasty (PTCA), coronary artery bypass graft, hypertensive encephalopathy, cerebrovascular accident, or transient ischemic attacks.
- •12. Patients with history/ current 2nd or 3rd degree atrioventricular block, long QT syndrome or corrected QT interval QTcï¼? >450msec or atrial fibrillation.
- •13. Patients with history of endocrine diseases such as hypercortisolism or polycystic ovary syndrome that may affect blood glucose levels.
- •14. Patients with history of pancreatitis, cholecystitis, gallstones and other digestive diseases.
- •15. Patients undergone weight loss surgery within 3 months before randomization or using weight-loss drugs (including traditional/herbal/ayurvedic/homeopathic) within 2 months.
- •randomization
- •16. Patients receiving oral or intravenous use of glucocorticoids or regular application (i.e continuous use more than one week within 4 weeks before randomization) with large doses of thiazide diuretics (hydrochlorothiazide, chlorothiazide, etc.).
- •17. Currently is participating in another investigational study or has participated in an investigational study within 90 days prior to randomization.
- •18. Any other serious disease or condition at screening (or randomization) that would compromise patient safety, might affect life expectancy, or make it difficult to successfully manage and follow the patient according to the protocol.
- •19. Patients with the current/past infections such as HIV, HBV and HCV.
研究者
相似试验
进行中（未招募）
3 期
A Clinical Study to Test the Effectiveness and Side Effects of Hetero-Tocilizumab in Severe COVID-19 PatientsCTRI/2021/05/033703Hetero Biopharma Limited
进行中（未招募）
不适用
Phase III, multicentre study assessing the efficacy and safety of Dysport compared to a Placebo for the treatment of upper limb spasticity in adult patients with hemiparesis.Arm SpasticityMedDRA version: 14.1Level: LLTClassification code 10048970Term: Arm spasticitySystem Organ Class: 100000004852EUCTR2010-019069-28-PLIpsen Innovation228
进行中（未招募）
1 期
Phase III, multicentre study assessing the efficacy and safety of Dysport compared to a Placebo for the treatment of upper limb spasticity in adult patients with hemiparesis.Arm SpasticityMedDRA version: 13.1Level: LLTClassification code 10048970Term: Arm spasticitySystem Organ Class: 10029205 - Nervous system disordersEUCTR2010-019069-28-SKIpsen Innovation228
进行中（未招募）
不适用
Phase III, multicentre study assessing the efficacy and safety of Dysport compared to a Placebo for the treatment of upper limb spasticity in adult patients with hemiparesis.EUCTR2010-019069-28-HUIpsen Innovation228
进行中（未招募）
不适用
Phase III, multicentre study assessing the efficacy and safety of Dysport compared to a Placebo for the treatment of upper limb spasticity in adult patients with hemiparesis.Arm SpasticityMedDRA version: 14.1Level: LLTClassification code 10048970Term: Arm spasticitySystem Organ Class: 100000004852EUCTR2010-019069-28-CZIpsen Innovation228